Radionuclide Therapy: Eligibility & Toxicity Monitoring

Quick Answer

Radioligand therapy is delivered in cycles gated by organ-at-risk tolerance, so the practical workflow is eligibility → per-cycle labs → organ-specific mitigation → toxicity surveillance. Across agents the dose-limiting organs are the bone marrow (myelosuppression), kidneys (especially PRRT), and salivary/lacrimal glands (PSMA). Two agent-specific protections are essential: amino-acid co-infusion to protect the kidneys in ¹⁷⁷Lu-DOTATATE PRRT, and awareness that PSMA therapy previews salivary toxicity on the diagnostic scan. Each cycle proceeds only if counts and organ function meet thresholds.

Eligibility (Before Cycle 1)

• Target confirmed on the companion diagnostic (adequate PSMA/SSTR expression; FDG discordance addressed).
• Adequate marrow reserve — commonly Hb ≥ ~9 g/dL, WBC/ANC and platelets above protocol thresholds (e.g., platelets ≥ ~75–100 ×10⁹/L).
• Adequate renal function — GFR/creatinine within protocol limits (measured GFR where it matters).
• Adequate hepatic function and performance status; pregnancy excluded; life expectancy consistent with benefit.

Organs at Risk by Agent

Per-Cycle Monitoring

• CBC before each cycle and through the nadir (~4–6 weeks) — hold/delay/reduce for cytopenias per protocol.
• Renal function each cycle (cumulative renal dose in PRRT); track for delayed nephrotoxicity.
• LFTs and, for relevant agents, electrolytes.
• Symptom review: xerostomia/dry eyes (PSMA), nausea (PRRT amino-acid infusion), fatigue, pain flare, marrow symptoms.

Organ-Specific Mitigation

• Kidneys (PRRT): amino-acid co-infusion competitively reduces proximal-tubular reabsorption of the peptide → lower renal dose; hydration; the infusion itself causes nausea/hyperkalemia — anticipate.
• Salivary (PSMA): the salivary/lacrimal avidity on the diagnostic PSMA scan previews the xerostomia of therapy; mitigation (cooling, sialagogues) has limited proven benefit — counsel patients.
• Marrow: dose- and cycle-cumulative; watch for prolonged cytopenias and secondary MDS/leukemia (long-term).

Toxicity Surveillance (Delayed)

• Nephrotoxicity (PRRT) can be delayed months–years — continue renal follow-up after treatment ends.
• Secondary MDS/AML — a small long-term risk across beta therapies.
• Xerostomia/dry eye (PSMA) — often persistent.

Common Pitfalls

• Omitting amino-acid renal protection in ¹⁷⁷Lu-DOTATATE PRRT.
• Treating despite sub-threshold counts or declining renal function.
• Forgetting renal dose is cumulative and nephrotoxicity may be delayed.
• Not counseling PSMA patients that salivary uptake on the scan previews xerostomia.

Board Pearls

Radioligand therapy is cycled and gated by organ-at-risk tolerance: the dose-limiting organs across agents are marrow (myelosuppression), kidneys (PRRT), and salivary/lacrimal glands (PSMA). Each cycle proceeds only if counts and renal/hepatic function meet protocol thresholds, and renal dose is cumulative.

Two agent-specific essentials: amino-acid (lysine/arginine) co-infusion protects the kidneys in ¹⁷⁷Lu-DOTATATE PRRT (reduces tubular reabsorption; itself causes nausea/hyperkalemia), and PSMA therapy's xerostomia is previewed by salivary/lacrimal uptake on the diagnostic PSMA scan — with limited proven mitigation.

Nephrotoxicity in PRRT can be delayed months–years — continue renal surveillance after therapy. A small long-term secondary MDS/AML risk applies across beta therapies. Y-90 radioembolization requires pre-therapy MAA lung-shunt/flow mapping to protect lungs and prevent non-target (GI) delivery; I-131 for diffuse pulmonary metastases respects lung-dose limits to avoid pneumonitis/fibrosis.

Related Pages

• Physics: Dosimetry in theranostics; therapy: ¹⁷⁷Lu-DOTATATE, ¹⁷⁷Lu-PSMA-617; safety: Radiation safety & patient release.

Figure / Diagram Suggestions

• An eligibility → per-cycle labs → mitigation → surveillance workflow.
• An organ-at-risk by agent matrix with mitigations.

Self-Check